Stocktoria
Evommune, Inc. EVMN
NYSE · stock · Pharmaceutical Preparations · website · IPO 2025-11-06
Evommune, Inc. financials (annual)
Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $13.0M | $7.0M |
| R&D expense | $74.0M | $64.2M |
| Operating income | -$81.1M | -$70.0M |
| Income tax | $0 | $0 |
| Net income | -$68.9M | -$66.8M |
| EPS (diluted) | $-11.22 | $-45.29 |
| Operating cash flow | -$76.4M | -$58.2M |
| Free cash flow | -$76.7M | -$58.3M |
| Cash & equivalents | $44.1M | $16.3M |
| Total assets | $224.9M | $76.1M |
| Total liabilities | $19.4M | $28.5M |
| Shareholders' equity | $205.6M | -$144.2M |
Growth · year-over-year · Revenue CAGR 85.7%
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue growth | +85.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.